UnknownNot Applicable

Screening of Gastrointestinal Tract Bleeding Causes Among Chronic Renal Failure Patients

100 participantsStarted 2020-10-01

Plain-language summary

The aim of the current study is to screen different causes and characteristics of Gastrointestinal bleeding in Chronic Renal Failure patients at Assuit University Hospital according to their stages based on e GFR (Stage I to IV), in order to assess different modalities of therapeutic intervention from medical therapy up to therapeutic intervention.

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * One hundred Chronic Renal Failure patients with different stages (stage I to IV) according to the National Kidney Foundation are recruited from inpatients of renal unit in internal medicine department, Assuit university hospitals. Their GFR will assessed by using Chronic Renal Failure EPI equation measured as GFR=166 x(s cr/0.7)-1.209X(0.993)age if female, and GFR=163X(s cr/0.9)-1.209x(0.993)age if male. (Andrews et al 2008). Chronic Renal Failure staging according to GFR by Chronic Renal Failure EPI is: * Stage1 in which GFR\>90 mil/min but evidence of kidney damage. * Stage 2 GFR 60-89 mil/min. * Stage 3 GFR 30-95 mil/min. * Stage 4 GFR 15-29 mil/min. * Stage 5 GFR\<15 mil/min. Exclusion Criteria: * All Patients with local causes of Gastrointestinal Bleeding * Benign and Malignant tumors in Gastrointestinal Tract. * Patients with Hemorrhoids or anal fissures. * Patients with Mallory-Weiss tears. * patients with Diverticular disease. * patients with Colon polyps. * patients with infectious causes of GIT bleeding (Salmonella, Shigella) * patients with Angiodysplasia. * patients with Esophageal varices

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Assessment of different modalities of therapeutic intervention.

Timeframe: one year from October 2020 to October 2021

Trial details

NCT IDNCT04491669

SponsorAssiut University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-10-01

Contact for this trial

Mahmoud EMH Mandou

00201006810538 m1234mandour@outlook.com

View on ClinicalTrials.gov More CKD trials

Plain-language summary

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.